logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Oncology drugs

    FiltersReset Filters
    210 results

    • abraxane

      (Paclitaxel)
      Abraxis BioScience, LLC
      Usage: ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.

    • actimmune

      (Interferon gamma-1b)
      Horizon Therapeutics USA, Inc.
      Usage: ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).

    • adcetris

      (brentuximab vedotin)
      SEAGEN INC.
      Usage: ADCETRIS is indicated for treating adult and pediatric patients with previously untreated or relapsed classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), as well as for consolidation post-transplant in high-risk cHL. It is used in combination with specific chemotherapy regimens.

    • adstiladrin

      (nadofaragene firadenovec-vncg)
      Ferring Pharmaceuticals
      Usage: ADSTILADRIN® is indicated for treating high-risk BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) in adults, specifically for those with carcinoma in situ (CIS) with or without papillary tumors.

    • afinitor

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

    • akynzeo

      (Netupitant and Palonosetron)
      Helsinn Therapeutics (U.S.), Inc.
      Usage: AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing cancer chemotherapy, particularly highly emetogenic regimens. It is used in combination with dexamethasone and consists of palonosetron and netupitant (or fosnetupitant in the injection form).

    • alecensa

      (ALECTINIB HYDROCHLORIDE)
      Genentech, Inc.
      Usage: ALECENSA is indicated for the adjuvant treatment of adults with resected ALK-positive non-small cell lung cancer (NSCLC), and for the treatment of adult patients with metastatic ALK-positive NSCLC, both as detected by an FDA-approved test.

    • alunbrig

      (brigatinib)
      Takeda Pharmaceuticals America, Inc.
      Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.

    • aphexda

      (Motixafortide)
      BioLineRx USA Inc
      Usage: APHEXDA is indicated, in combination with filgrastim (G-CSF), for mobilizing hematopoietic stem cells into peripheral blood for collection and autologous transplantation in patients with multiple myeloma.

    • arimidex

      (Anastrozole)
      ANI Pharmaceuticals, Inc.
      Usage: ARIMIDEX is indicated for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatment of hormone receptor-positive or unknown locally advanced and metastatic breast cancer, particularly after disease progression on tamoxifen therapy.
      • ...